[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].
Identifieur interne : 001C49 ( Ncbi/Merge ); précédent : 001C48; suivant : 001C50[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].
Auteurs : A. Guillard ; C. Chastang ; G. FenelonSource :
- Revue neurologique [ 0035-3787 ] ; 1986.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Levodopa.
- diagnosis : Parkinson Disease.
- mortality : Parkinson Disease.
- therapy : Parkinson Disease.
- Follow-Up Studies, Humans, Prognosis.
Abstract
As L-Dopa was marketed in France in 1971 for treatment of Parkinson's disease we used 1971 to divide a sample of patients into 2 groups. Group 1 (152 patients) includes patients with diagnosis made before 1971 and group 2 (264 patients) with diagnosis after 1971. The prognostic factors were motor deterioration, intellectual deterioration and death. The prognostic variables include the neuro-psychological status at the onset of the disease and at the beginning of L-Dopa treatment. The statistical analysis is based on Kaplan-Meier estimate, Log-rank test and Cox's model. In group 2, 10 years after the beginning treatment of L-Dopa, motor deterioration affected 60 p. 100 of the patients. The poor variables were akineto-hypertonic type, severe akinesia, poor clinical result after one year. Intellectual deterioration was frequent: 30 p. 100 at 10 years. The poor variables were age over 60, depression or psychotic episodes occurring during the first year. The 10 years-survival rate was 64 p. 100 and was not different from that recorded in a French population of same age and sex distribution. The poor variables were severe akinesia, presence of a Babinski sign, poor therapeutic result after one year, occurrence of psychotic episodes during the first year. The interval between the onset of the disease and the beginning of L-Dopa did not have any prognostic value, whatever the response criterion. In group 1, the same prognostic factors were pointed out. Survival and intellectual deterioration were not different in the 2 groups, but in group 1, motor deterioration appeared earlier.(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed: 3797924
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001883
- to stream PubMed, to step Curation: 001842
- to stream PubMed, to step Checkpoint: 001842
Links to Exploration step
pubmed:3797924Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].</title><author><name sortKey="Guillard, A" sort="Guillard, A" uniqKey="Guillard A" first="A" last="Guillard">A. Guillard</name></author><author><name sortKey="Chastang, C" sort="Chastang, C" uniqKey="Chastang C" first="C" last="Chastang">C. Chastang</name></author><author><name sortKey="Fenelon, G" sort="Fenelon, G" uniqKey="Fenelon G" first="G" last="Fenelon">G. Fenelon</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1986">1986</date><idno type="RBID">pubmed:3797924</idno><idno type="pmid">3797924</idno><idno type="wicri:Area/PubMed/Corpus">001883</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001883</idno><idno type="wicri:Area/PubMed/Curation">001842</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001842</idno><idno type="wicri:Area/PubMed/Checkpoint">001842</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001842</idno><idno type="wicri:Area/Ncbi/Merge">001C49</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].</title><author><name sortKey="Guillard, A" sort="Guillard, A" uniqKey="Guillard A" first="A" last="Guillard">A. Guillard</name></author><author><name sortKey="Chastang, C" sort="Chastang, C" uniqKey="Chastang C" first="C" last="Chastang">C. Chastang</name></author><author><name sortKey="Fenelon, G" sort="Fenelon, G" uniqKey="Fenelon G" first="G" last="Fenelon">G. Fenelon</name></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="1986" type="published">1986</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Follow-Up Studies</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (mortality)</term><term>Parkinson Disease (therapy)</term><term>Prognosis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Follow-Up Studies</term><term>Humans</term><term>Prognosis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As L-Dopa was marketed in France in 1971 for treatment of Parkinson's disease we used 1971 to divide a sample of patients into 2 groups. Group 1 (152 patients) includes patients with diagnosis made before 1971 and group 2 (264 patients) with diagnosis after 1971. The prognostic factors were motor deterioration, intellectual deterioration and death. The prognostic variables include the neuro-psychological status at the onset of the disease and at the beginning of L-Dopa treatment. The statistical analysis is based on Kaplan-Meier estimate, Log-rank test and Cox's model. In group 2, 10 years after the beginning treatment of L-Dopa, motor deterioration affected 60 p. 100 of the patients. The poor variables were akineto-hypertonic type, severe akinesia, poor clinical result after one year. Intellectual deterioration was frequent: 30 p. 100 at 10 years. The poor variables were age over 60, depression or psychotic episodes occurring during the first year. The 10 years-survival rate was 64 p. 100 and was not different from that recorded in a French population of same age and sex distribution. The poor variables were severe akinesia, presence of a Babinski sign, poor therapeutic result after one year, occurrence of psychotic episodes during the first year. The interval between the onset of the disease and the beginning of L-Dopa did not have any prognostic value, whatever the response criterion. In group 1, the same prognostic factors were pointed out. Survival and intellectual deterioration were not different in the 2 groups, but in group 1, motor deterioration appeared earlier.(ABSTRACT TRUNCATED AT 250 WORDS)</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3797924</PMID><DateCreated><Year>1987</Year><Month>02</Month><Day>03</Day></DateCreated><DateCompleted><Year>1987</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Print"><Volume>142</Volume><Issue>3</Issue><PubDate><Year>1986</Year></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].</ArticleTitle><Pagination><MedlinePgn>207-14</MedlinePgn></Pagination><Abstract><AbstractText>As L-Dopa was marketed in France in 1971 for treatment of Parkinson's disease we used 1971 to divide a sample of patients into 2 groups. Group 1 (152 patients) includes patients with diagnosis made before 1971 and group 2 (264 patients) with diagnosis after 1971. The prognostic factors were motor deterioration, intellectual deterioration and death. The prognostic variables include the neuro-psychological status at the onset of the disease and at the beginning of L-Dopa treatment. The statistical analysis is based on Kaplan-Meier estimate, Log-rank test and Cox's model. In group 2, 10 years after the beginning treatment of L-Dopa, motor deterioration affected 60 p. 100 of the patients. The poor variables were akineto-hypertonic type, severe akinesia, poor clinical result after one year. Intellectual deterioration was frequent: 30 p. 100 at 10 years. The poor variables were age over 60, depression or psychotic episodes occurring during the first year. The 10 years-survival rate was 64 p. 100 and was not different from that recorded in a French population of same age and sex distribution. The poor variables were severe akinesia, presence of a Babinski sign, poor therapeutic result after one year, occurrence of psychotic episodes during the first year. The interval between the onset of the disease and the beginning of L-Dopa did not have any prognostic value, whatever the response criterion. In group 1, the same prognostic factors were pointed out. Survival and intellectual deterioration were not different in the 2 groups, but in group 1, motor deterioration appeared earlier.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guillard</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chastang</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fenelon</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Etude à long terme de 416 cas de maladie de Parkinson. Facteurs de pronostic et implications thérapeutiques.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3797924</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Chastang, C" sort="Chastang, C" uniqKey="Chastang C" first="C" last="Chastang">C. Chastang</name><name sortKey="Fenelon, G" sort="Fenelon, G" uniqKey="Fenelon G" first="G" last="Fenelon">G. Fenelon</name><name sortKey="Guillard, A" sort="Guillard, A" uniqKey="Guillard A" first="A" last="Guillard">A. Guillard</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001C49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:3797924
|texte= [Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:3797924" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |